Quantum
Home > Boards > US OTC > Miscellaneous >

Therapeutic Solutions International, Inc. (TSOI)

TSOI RSS Feed
Add TSOI Price Alert      Hide Sticky   Hide Intro
Moderator: subslover, centsability4me, DD_dempsey, emptypants
Search This Board: 
Last Post: 11/17/2018 11:21:55 AM - Followers: 139 - Board type: Free - Posts Today: 0



Therapeutic Solutions International is focused on immune modulation
                    for the treatment of several specific diseases

TSOI Products

5 Biologics, 6 Nutraceuticals, 1 Pharmaceutical  = 12

6 TSOI nutraceutical products released from granted patent
Projuvenol, NanoStilbene, DermalStilbene, IsoStilbene, NeuroStilbene, Alpha Lipoic Acid
https://patents.google.com/patent/US9682047B2/en


4 TSOI nutraceutical products for sale online
Projuvenol, Nanostilbene, DermalStilbene, NeuroStilbene
http://www.youcanordernow.com/

5 Biologics, 1 Pharmaceutical licensed to Pan Am Cancer Treatment Center in Mexico
StemVacs, Cancer Metabolic DeTox, innaMune, LymphoBoost, MemoryMune, BRS-001
http://ih.advfn.com/p.php?pid=nmona&article=77606645
http://ih.advfn.com/p.php?pid=nmona&article=77309980
http://ih.advfn.com/p.php?pid=nmona&article=77635806

Pan Am Cancer Treatment Center Introductory Tour Video
https://www.youtube.com/watch?v=rWgJLRCICa8&feature=youtu.be



News

NEWS : 10/25/18
http://ih.advfn.com/p.php?pid=nmona&article=78538984

Therapeutic Solutions International Announces CTE Optimized NeuroStilbene Formulation

NEWS : 9/25/18
https://ih.advfn.com/p.php?pid=nmona&article=78326088

Therapeutic Solutions International Files Patent on Clinical Data Demonstrating Reduction of Inflammatory Cytokines Using NanoStilbeneTM

NEWS : 9/19/2018
https://ih.advfn.com/p.php?pid=nmona&article=78289796

Dr. Santosh Kesari

Therapeutic Solutions International Collaborates with Internationally Renowned Neurologist and NFL Charger Hall of Famer to Develop New Intellectual Property for Treatment of Chronic Traumatic Encephalopathy
Company Files Patent and Generates Proof of Concept Data using NeuroStilbene for Prevention of Football Associated Brain Damage


NEWS : 9/4/18
https://ih.advfn.com/p.php?pid=nmona&article=78186786

Therapeutic Solutions International Completes Phase 1 Clinical Trial in Advanced Cancer Patients for Right to Try Access
of its StemVacs Product for American Cancer Patients

Company to use Phase I Data of its Cancer Stem Cell Immunotherapy to Allow for use in the USA under President Donald Trump's
Right to Try Law



NEWS : 8/22/18
https://ih.advfn.com/p.php?pid=nmona&article=78119448

Wes Chandler

Therapeutic Solutions International Recruits NFL Chargers Hall of Famer Wes Chandler to Lead NeuroStilbene for Chronic Traumatic Encephalopathy in Football Players
Company to Advance NeuroStilbene Product for High-Performance Athletes
Susceptible to Head Injuries


NEWS : 8/13/18
https://ih.advfn.com/p.php?pid=nmona&article=78060284

Therapeutic Solutions International Reports Synergistic Enhancement of Ozone Therapy Efficacy in Prostate, Breast and Ovarian Cancer Cells by Pterostilbene
Clinical Stage Cancer Immunotherapy Biotechnology Company Files Patent Expanding Uses of its Pterostilbene Based Product Pipeline


NEWS : 8/6/18
https://ih.advfn.com/p.php?pid=nmona&article=78013140

Therapeutic Solutions International Develops Microemulsion Formulation of
Alpha Lipoic Acid for Intranasal Delivery


Company Expands Product Pipeline in Neurodegenerative Arena

NEWS : 7/23/18
https://ih.advfn.com/p.php?pid=nmona&article=77913150

Dr. Francesco Marincola

Therapeutic Solutions International Recruits Internationally Recognized Cancer Immunotherapy Pioneer Dr. Francesco Marincola to Accelerate StemVacs and NanoStilbene Clinical Development
Company Focuses on Non-Toxic Therapies Using Immune System
to Selectively Kill Cancer Cells through Immunotherapy


NEWS : 7/16/18
https://ih.advfn.com/p.php?pid=nmona&article=77868683

Therapeutic Solutions International, Inc., Releases Intranasal Formulation of Pterostilbene for
Rapid Access to Blood-Brain Barrier
Company Expands its Pterostilbene Based Portfolio into Brain Cancers

Oceanside, CA -- July 16, 2018 -- Investorshub NewsWire -- Therapeutics Solutions International, Inc., (OTC Markets: TSOI) announced today the release of NeuroStilbene, a proprietary nano-formulation of pterostilbene formulated for intranasal delivery.

NEWS : 7/9/18
https://ih.advfn.com/p.php?pid=nmona&article=77825316

Dr. Juergen Winkler

Therapeutic Solutions International, Inc., Appoints Juergen Winkler, MD, ABIHM to Scientific Advisory Board
Pioneer of Functional Medicine Teams Up with Clinical Stage Biotechnology Company in Commercialization of Non-Toxic Immunotherapy


NEWS : 7/2/18
https://ih.advfn.com/p.php?pid=nmona&article=77784227

Therapeutic Solutions International Announces Clinical Proof of Concept of Nanoparticle Pterostilbene Formulation: NanoStilbene™
Early Clinical Trial Data Supports Enhanced Biodistribution of NanoStilbene™ Compared to Standard Pterostilbene When Orally Administered


NEWS : 6/25/18
https://ih.advfn.com/p.php?pid=nmona&article=77734511

Therapeutic Solutions International Releases "IsoStilbene" Injectable Formulation of Pterostilbene Under Granted Patent for Augmentation of Immunotherapy and Targeting of Cancer Stem Cells . IsoStilbene to be Included in Pan American Cancer Treatment Center Protocols

NEWS : 6/18/18
https://ih.advfn.com/p.php?pid=nmona&article=77684969

Therapeutic Solutions International Announces the Appointment of James Veltmeyer, MD as Chief Medical Officer

Dr. James Veltmeyer

Oceanside, CA -- June 18, 2018 -- InvestorsHub NewsWire -- Therapeutics Solutions International, Inc., (OTC Markets: TSOI) previously announced their plans to provide access to its clinical stage cancer immunotherapy product StemVacs under the Right To Try law signed by President Trump on May 30th 2018, and have appointed Dr. James Veltmeyer as Chief Medical Officer of their future planned cancer clinic.

NEWS : 6/11/18
http://ih.advfn.com/p.php?pid=nmona&article=77635806

Therapeutic Solutions International Expands Adoptive Immunotherapy Portfolio by Incorporation of "Universal Cancer Antigen" into StemVacs Dendritic Cell Platform

OCEANSIDE, CA -- June 11, 2018 -- InvestorsHub NewsWire -- Therapeutics Solutions International, Inc., (OTC Markets: TSOI) announced today initiation of efforts to combine its existing CTCFL "universal cancer antigen", labeled as BRS-001, with its clinical stage StemVacs Dendritic Cell Platform.

BORIS Info:
http://stemvacs.com/?page_id=145

NEWS : 6/6/18
http://ih.advfn.com/p.php?pid=nmona&article=77606645

Therapeutic Solutions International Announces Licensing of Additional Technologies to
Pan American Cancer Treatment Center


Patent Title: Targeting the Tumor Microenvironment through Nutraceutical Based Immunoadjuvants : Cancer Metabolic DeTox
http://www.marketwired.com/press-release/therapeutic-solutions-files-new-patent-on-targeting-tumor-microenvironment-through-nutraceutical-otc-pink-tsoi-2215015.htm
Patent Title: Methods of Re-Activating Dormant Memory Cells with Anticancer Activity : MemoryMune
http://www.marketwired.com/press-release/therapeutic-solutions-files-patent-on-methods-re-activating-dormant-memory-cells-with-otc-pink-tsoi-2220094.htm
Patent Title: Stimulation of Immunity to Tumor Stem Cell Specific Proteins by Peptide Immunization : StemVacs
http://www.marketwired.com/press-release/therapeutic-solutions-international-announces-filing-new-immunotherapy-patent-exclusive-otc-pink-tsoi-2208787.htm
Patent Title:Augmentation of Anti-Tumor Immunity by Mifepristone and Analogues Thereof : LymphoBoost
http://www.marketwired.com/press-release/therapeutic-solutions-files-new-patent-on-augmentation-anti-tumor-immunity-mifepristone-otc-pink-tsoi-2217703.htm
Patent Title: Activated Leukocyte Extract for Repair of Innate Immunity in Cancer Patients : innaMune
http://www.marketwired.com/press-release/therapeutic-solutions-files-patent-on-blood-derived-innate-immune-system-stimulator-otc-pink-tsoi-2216672.htm

Pan Am Cancer Treatment Center
Telephone: (619) 735-9581
Diego Rivera #2339 suite 108
Zona Rio, Tijuana B.C. 22010
www.cancerimmunotherapy.mx
info@cancerimmunotherapy.mx
Pan Am Cancer Treatment Center Intoductory video :
https://www.youtube.com/watch?v=rWgJLRCICa8&feature=youtu.be

NEWS : 5/31/18
http://ih.advfn.com/p.php?pid=nmona&article=77561606

Therapeutic Solutions International to Provide Patients Access to StemVacs Cancer Immunotherapy through Newly Passed Right to Try Law

NEWS : 5/21/18
http://ih.advfn.com/p.php?pid=nmona&article=77477228

Therapeutic Solutions International Releases "DermalStilbene" a Topical Formulation of Pterostilbene

NEWS : 5/15/18
http://ih.advfn.com/p.php?pid=nmona&article=77431704

Therapeutic Solutions International, Inc., to Initiate Clinical Trial of Patented Cancer Immunotherapy Adjuvant Nanostilbene

NEWS : 5/9/18
http://ih.advfn.com/p.php?pid=nmona&article=77382606

Dr. Nassir Azimi

Therapeutic Solutions International, Inc., Announces the Appointment of Nassir Azimi, MD, to Science Board
Company to Iniate Investigational Cardiovascular Study with Dr. Azimi and Nanostilbene


NEWS : 5/1/18
http://ih.advfn.com/p.php?pid=nmona&article=77309980

Therapeutic Solutions International Launches Multi-Protocol Cancer Immunotherapy Clinical Trial with Pan Am Cancer Treatment
Company Aims to Leverage Transfer Factor Pulsed Autologous Dendritic Cells on StemVacs Platform with
Patented Augmenter of Cancer Immunotherapy NanoStilbene


Link to Pan Am Cancer Treatment Centers website :
http://cancerimmunotherapy.mx/web/

Link to TSOI Patent covering NanoStilbene :
https://patents.google.com/patent/US9682047B2/en

StemVacs is also the subject of a filed Investigational New Drug Application (IND #17448) with the U.S. FDA. The IND seeks to establish safety and immune response of cancer, targeting a new personalized dendritic cell vaccine.
StemVacs Website :
http://stemvacs.com
Link to BORIS/StemVacs patent application :
https://patents.google.com/patent/US20170143812

TSOI  RTT

Therapeutic Solutions International Completes Phase 1 Clinical Trial in Advanced Cancer Patients for Right to Try Access
of its StemVacs Product for American Cancer Patients  9/4/18

https://ih.advfn.com/p.php?pid=nmona&article=78186786


StemVacs Immunotherapy Platform for TSOI  RTT Cancer Clinic
http://stemvacs.com/

StemVacs  Patents - Products - PRs


Patent Title: Targeting the Tumor Microenvironment through Nutraceutical Based Immunoadjuvants  Cancer Metabolic DeTox
http://www.marketwired.com/press-release/therapeutic-solutions-files-new-patent-on-targeting-tumor-microenvironment-through-nutraceutical-otc-pink-tsoi-2215015.htm
Patent Title: Methods of Re-Activating Dormant Memory Cells with Anticancer Activity  MemoryMune
http://www.marketwired.com/press-release/therapeutic-solutions-files-patent-on-methods-re-activating-dormant-memory-cells-with-otc-pink-tsoi-2220094.htm
Patent Title: Stimulation of Immunity to Tumor Stem Cell Specific Proteins by Peptide Immunization  StemVacs
http://www.marketwired.com/press-release/therapeutic-solutions-international-announces-filing-new-immunotherapy-patent-exclusive-otc-pink-tsoi-2208787.htm
Patent Title:Augmentation of Anti-Tumor Immunity by Mifepristone and Analogues Thereof  LymphoBoost
http://www.marketwired.com/press-release/therapeutic-solutions-files-new-patent-on-augmentation-anti-tumor-immunity-mifepristone-otc-pink-tsoi-2217703.htm
Patent Title: Activated Leukocyte Extract for Repair of Innate Immunity in Cancer Patients  innaMune
http://www.marketwired.com/press-release/therapeutic-solutions-files-patent-on-blood-derived-innate-immune-system-stimulator-otc-pink-tsoi-2216672.htm
Therapeutic Solutions International Expands Adoptive Immunotherapy Portfolio by Incorporation of "Universal Cancer Antigen" into StemVacs Dendritic Cell Platform  BRS-001
http://ih.advfn.com/p.php?pid=nmona&article=77635806

FDA RTT page for patients:
https://www.fda.gov/ForPatients/Other/ucm625115.htm

TSOI CTE



Military personnel show brain changes similar to those in retired football players suspected to have CTE  7/17/18
http://newsroom.ucla.edu/releases/military-personnel-brain-changes-similar-retired-football-players-suspected-cte


60 Minutes article on Combat Veterans suffering from CTE as NFL faces its own health crisis  1/7/18
https://www.cbssports.com/nfl/news/60-minutes-combat-veterans-suffering-from-cte-as-nfl-faces-its-own-health-crisis/

60 minutes article on Combat Veterans Coming Home With CTE   9/16/18
https://www.cbsnews.com/news/60-minutes-combat-veterans-coming-home-with-cte-brain-injury/


Tony Hawk on CTE in Extreme Sports: “It’s Absolutely a Concern”
https://www.mensjournal.com/sports/tony-hawk-on-cte-in-extreme-sports-its-absolutely-a-concern-w207982/

Boston University Study Finds CTE In 110 Of 111 Brains of Former NFL Players
https://www.si.com/nfl/2017/07/25/boston-university-study-cte-nfl-player-brains

Wes Chandler to lead Development of NeuroStilbene for CTE
Therapeutic Solutions International Recruits NFL Chargers Hall of Famer Wes Chandler to Lead NeuroStilbene for Chronic Traumatic Encephalopathy in Football Players
Company to Advance NeuroStilbene Product for High-Performance Athletes Susceptible to Head Injuries  8/22/18

https://ih.advfn.com/p.php?pid=nmona&article=78119448

Wes Chandler and Dr. Santosh Kesari collaborate on CTE Patent
after TSOI generates Proof of Concept Data using NeuroStilbene for Prevention of Football - Associated Brain Damage   9/19/18
https://ih.advfn.com/p.php?pid=nmona&article=78289796


TSOI CTE Advisory Board
https://therapeuticsolutionsint.com/?page_id=551



TSOI R&D

StemVacs Phase 1 clinical trials @ Pan Am Cancer Treatment Center
Announced  5/1/18

http://ih.advfn.com/p.php?pid=nmona&article=77309980
Completed  9/4/18
Results :
https://ih.advfn.com/p.php?pid=nmona&article=78186786

Pilot pharmacokinetic trial of NanoStilbene for dosage /efficacy monitored by Dr. James Veltmeyer
Announced  5/15/18
http://ih.advfn.com/p.php?pid=nmona&article=77431704
Completed  7/2/18
Results :
http://ih.advfn.com/p.php?pid=nmona&article=77784227

A small pilot study is in the planning stages to be performed under the direction of Dr. Santosh Kesari at John Wayne Cancer Institute in Santa Monica CA. by conducting a clinical trial assessing the effects of pterostilbene in modulating immune response and inflammatory parameters in a group of advanced solid tumor cancer patients.
Announced  4/17/18
https://www.sec.gov/Archives/edgar/data/1419051/000107878218000437/f10k123117_10k.htm
Completed   9/25/18
Results :
https://ih.advfn.com/p.php?pid=nmona&article=78326088


A small pilot study is in the planning stages to be performed under the direction of Dr. Nassir Azimi in San Diego CA. by conducting a study using NanoStilbene in a group of heart attack patients :
http://ih.advfn.com/p.php?pid=nmona&article=78098528
Announced 5/9/18
http://ih.advfn.com/p.php?pid=nmona&article=77382606


TSOI Patents
http://therapeuticsolutionsint.com/?page_id=68

Patent Filed  Patent Name Press Release
 07-08-15  Augmentation of Oncology Immunotherapies by Pterostilbene Containing Compositions  07-09-15
 09-02-15  Preventative Methods and Therapeutic or Pharmaceutical Compositions for the Treatment or Prevention of Pregnancy Complications 09-08-15
 09-15-15  Diagnostic Methods For The Assessment Of Pregnancy Complications 09-21-15
 09-25-15  A Medical Device For Reducing The Risk Of Preterm-Labor And Preterm-Birth 09-29-15
04-27-16  Augmentation Of Stem Cell Activity Using Pterostilbene And Compositions Containing Pterostilbene  04-28-16
 03-29-17  Stimulation of Immunity to Tumor Stem Cell Specific Proteins by Peptide Immunization 04-10-17
 03-29-17  Targeting the Tumor Microenvironment through Nutraceutical Based Immunoadjuvants  05-09-17
 03-29-17  Activated Leukocyte Extract for Repair of Innate Immunity in Cancer Patients  05-16-17
 03-29-17  Augmentation of Anti-Tumor Immunity by Mifepristone and Analogues Thereof 05-22-17
 03-29-17  Methods of Re-Activating Dormant Memory Cells with Anticancer Activity 06-05-17
 10-08-17 Synergistic Inhibition of Glioma Using Pterostilbene and Analogues Thereof 10-16-17
 08-13-18 Enhancement of Ozone Therapy using Pterostilbene 08-13-18
 09-17-18 Pterostilbene and Compositions Thereof for Prevention and Treatment of Chronic Traumatic Encephalopathy 09-19-18
 09-25-18 Pterostilbene and Formulations Thereof for Treatment of Pathological Immune Activation 09-25-18


TSOI Scientific Advisory Board Members
https://therapeuticsolutionsint.com/?page_id=64


Dr. Santosh Kesari is a board-certified neurologist and neuro-oncologist and is currently Chair, Department of Translational Neuro-Oncology and Neurotherapeutics, John Wayne Cancer Institute.

He is also Director of Neuro-Oncology, Providence Saint John’s Health Center and Member, Los Angeles Biomedical Research Institute. Dr. Kesari is ranked among the top 1% of neuro-oncologists and neurologists in the nation, according to Castle Connolly Medical Ltd and an internationally recognized scientist and clinician. He is a winner of an Innovation Award by the San Diego Business Journal. He is on the advisory board of American Brain Tumor Association, San Diego Brain Tumor Foundation, Chris Elliott Fund, Nicolas Conor Institute, Voices Against Brain Cancer, and Philippine Brain Tumor Alliance. He has been the author of over 250 scientific publications, reviews, or books. He is the inventor on several patents and patent applications, and founder and advisor to many cancer and neurosciences focused biotech startups.

Dr. Kesari has had a long-standing interest in cancer stem cells and studies their role in the formation of brain tumors and resistance to treatment. He believes that in order to cure patients with brain tumors we first need to gain a better molecular and biological understanding of the disease. A physician/scientist, Kesari harnesses his experience in surgery, chemotherapy, immunotherapy, radiation therapy and novel devices to help develop Precision Therapeutic Strategies that will advance medicine to a new stage in the battle against brain tumors and eradicate the disease.

Dr. Franceso Marincola is currently Chief Science Officer at Refuge Biotechnologies, Menlo Park, California. Most recently, he served as a distinguished research fellow and strategist for immune oncology discovery at AbbVie, Inc Previously, he was the Inaugural Chief Research Officer of Sidra Medical and Research Centre in Doha, Qatar. He was previously a tenured Senior Investigator at the U.S. National Institutes of Health. He is past-President of the Society for the Immunotherapy of Cancer and Editor-in-Chief of the Journal of Translational Medicine.

Dr. Marincola received his MD summa cum laude from the University of Milan and did his surgery training at Stanford University, California. His scientific work deepened the understanding of the mechanisms leading to rejection of tumors or transplanted organs by the immune system and development of autoimmunity. With over 500 peer-reviewed scientific papers, Dr. Marincola is considered one of the world’s leading experts in cancer immunotherapy.

Dr. Pablo Guzman is a cardiologist in Fort Lauderdale, Florida where he is on staff at Holy Cross Hospital. He received his medical degree from University of Puerto Rico School of Medicine and his Cardiology Fellowship at The Johns Hopkins Hospital where he then spent the first part of his career continuing his basic science and clinical research along with his clinical duties. His CV includes over 25 papers published in peer-reviewed journals and more than 15 abstracts.

He is a Fellow of the American College of Cardiology and practiced for more than 30 years. Dr. Guzman is well experienced in basic and clinical research, having participated in many clinical trials. He is also the acting Chief Medical Officer of Variant Pharmaceuticals, a Specialty Pharma company developing treatments for kidney diseases.

Dr. Juergen Winkler is presently practicing at Quantum Functional Medicine in Carlsbad, CA, which he founded in July of 2012. In 2005 he was the co-founder of Genesis Health Systems (Integrative Cancer and Medical Treatment Center) located in Oceanside, CA. He has been a featured speaker for: the NSCC Women’s Health Seminar, Annual IPT/IPTLD Integrative Cancer Care Conference (Multiple years), Health Freedom Expo 2011 & 2012, the Japanese Society of Oxidative Medicine in Osaka Japan, ACOSPM 2010 & 2011 conferences, NSCC Health and Wellness Series 2013, and various other events. He is the physician author of Chapter 5 in the Defeat Cancer book and has been a featured physician in the Townsend Letter.

Dr. Nassir Azimi is a cardiologist in La Mesa, California and attended Dartmouth Medical School and completed his residency at the University of Colorado. He finished his four year fellowship in Cardiovascular and Peripheral Interventions at Yale University in New Haven. Dr. Azimi has been in private practice for over 13 years establishing a thriving clinical practice for cardiac patients as well as treating patients for peripheral vascular disease. He is active in Interventional Cardiology and Peripheral Interventions. Dr. Azimi is the director of La Mesa Cardiac Center’s Nuclear Cardiology Laboratory. He is also an investigator in multiple clinical research studies for various cardiac and peripheral diseases.

He has been recognized as San Diego’s Top Interventional Cardiologists by San Diego Magazine 2013,2014,2016, 2017 and also by Castle Connoly for 2013, 2014, 2015,2016, 2017, and 2018. He is a former chief of biomedical ethics (6 years), former chief of Medicine and former chief of Endovascular Medicine as well as Vice Chief of Cardiology at SGH. He is on the board of directors of the California ACC where he serves as chair of the public relations committee. He is on Editorial Review Board for multiple medical journals. He is a national speaker on various topics in cardiology and internal medicine.

Dr. James Veltmeyer is a board-certified family physician in La Mesa, California. A graduate of UC San Diego and the Ross University School of Medicine, he completed his residency through the UC San Francisco system where he became Chief of Family Medicine Residency, overseeing 36 doctors.

Dr. Veltmeyer, a member of the San Diego Critical Care Medical Group, has been elected for four years (2012, 2014, 2016, and 2017) by his colleagues in the San Diego County Medical Society as a “Physician of Exceptional Excellence,” the most prestigious honor awarded to a “Top Doctor” in San Diego County. He is among a select group of San Diego physicians who was chosen four of the last fifteen years and he consistently ranks in the top 1% to 2% for patient satisfaction. He is currently the Chief of the Department of Family Medicine at Sharp Grossmont Hospital where he provides senior leadership to over 200 doctors.

Dr. Barry Glassman, DMD, DAAPM, DAACP, FICCMO, Diplomate ABDSM, FADI, is a Diplomate of the American Academy of Craniofacial Pain and the American Academy of Pain Management, as well as a Fellow of the International College of Craniomandibular Orthopedics and the Academy of Dentistry International, he is also on staff at the Lehigh Valley Hospital where he serves as a resident instructor of Craniofacial Pain and Dysfunction and Dental Sleep Medicine.

Dr. Glassman is a Diplomate of the Academy of Dental Sleep Medicine. He is on the staff at the Sacred Heart Hospital Sleep Disorder Center, as well as serving as the Chief Dental Consultant to three other sleep centers in the Lehigh Valley. A popular and dynamic speaker, Dr. Glassman lectures internationally, as well as throughout the United States. In addition to his extensive schedule which includes guest lecture appearances and in-depth courses on joint dysfunction, chronic pain, headache, sleep disorders, and migraine headache, Dr. Glassman is a frequent speaker at major chronic pain and joint dysfunction professional conferences.

University of Pittsburgh: Bachelor of Science 1969, Pittsburgh, Pennsylvania University of Pittsburgh School of Dental Medicine; D.M.D. 1973, Pittsburgh Pennsylvania Post Graduate Hours in Craniomandibular Dysfunction and Sleep Disorders: Over 2500

Dr. Vijay Mahant has been involved in Research and Development in the medical industry for close to 30 years. Working in the FDA regulated medical industry, he has headed R&D activities for several bio-medical companies as well as being the founder, CEO & Chairman of MediLite, Inc.

Dr. Mahant has specialized in the areas of assay development, has numerous patents to his credit and has published extensively. Dr. Mahant received his B.S. in Biochemistry from the University of Salford, UK; a M.S. in Medicinal Chemistry and a Ph.D. in Medical Biochemistry from Lougborough University of Technology, UK.

Dr. David P. Hajjar is currently Professor of Biochemistry, at Weill Cornell Medical College and Professor of Pathology and Laboratory Medicine, Weill Cornell Medical College.

Professor Hajjar was also a Frank H.T. Rhodes Distinguished Professor of Cardiovascular Biology and Genetics, Pathology and Laboratory Medicine, Weill Cornell Medical College from 1998 – 2014. Currently Dr. Hajjar is Dean Emeritus and was Executive Vice Provost at Cornell University.

The principal aim of Dr. Hajjar’s work is to define the mechanisms by which Nitric Oxide (NO) and prostaglandin synthetic pathways interact to alter eicosanoid biosynthesis as well as to investigate the impact of these mediators on atherosclerosis and thrombosis. Over the years, he has defined the roles and mechanisms of these complex signaling interactions in order to gain an understanding of the pathophysiological processes in atherosclerosis using animal models and the consequences of pharmacological interventions.

In recent work, he has showed that the enzyme prostaglandin H2 synthase (PGHS, also known as cyclooxygenase) regulates the production of eicosanoids that modulate physiologic processes in the vessel wall, contributing to atherosclerosis and thrombosis. Dr. Hajjar demonstrated that various forms of NOx can have different modulatory effects on the activity of PGHS-1, the predominant isozyme in platelets. These and other studies revealed that the active heme center of PGHS-1 regulates peroxynitrite-induced modification and loss of enzyme reactivity, indicating that heme may play a decisive role in catalyzing these processes in PGHS-1 when exposed to nitrative stress in an inflammatory setting. Collectively, these studies show for the first time that iNOS influences PGHS expression and its activity, which can contribute to modification of an important enzyme involved in inflammation during atherosclerosis. Since iNOS-derived species are required for robust atherosclerosis-associated peroxynitrite production in peripheral organs, these studies have contributed importantly to our understanding of the complex alterations in eicosanoid metabolism that occur during the pathogenesis of heart disease where inflammation occurs.


TSOI Management
https://therapeuticsolutionsint.com/?page_id=62


Timothy G. Dixon – President, CEO, & Chairman

Mr. Dixon currently serves as Chief Executive Officer, President, and Chairman of Therapeutic Solutions International, Inc. Mr. Dixon previously served as the President of TMD Courses, Inc. from 2006 to 2012 and; as the President of Splint Decisions Inc. from 2010 to 2011. Mr. Dixon has attended hundreds of hours of continuing medical/dental education throughout the years and has produced many educational DVD’s used by dental professionals worldwide on the subject of parafunctional control, migraine prevention, therapeutic Botox injections, migraine pathophysiology, dental sleep medicine, and other therapeutic protocols. Mr. Dixon also has extensive experience in dealing with corporate compliance matters with the U.S. Food and Drug Administration, (FDA) as well as many international regulatory bodies.

Gerry B. Berg – Vice President, CFO, Director

Gerry B. Berg has served as our Vice-President and Chief Financial Officer since April 20, 2011.  Mr. Berg became a director of the Company on August 24, 2012.  Mr. Berg has over 30 years of senior management experience working with private and public companies.  From May 2010 to March 2011, Mr. Berg served as President and Chairman of the Board of Directors of Friendly Auto Dealers, Inc. and also served in a consulting capacity from March 2009 to May 2010.

Mr. Berg holds a Bachelors of Science in Accounting from Walsh College where he graduated Cum Laude.  Mr. Berg became a Certified Public Accountant in the State of Michigan in 1979 and in the State of California in 1984.  Mr. Berg does not currently practice as a Certified Public Accountant.

Thomas E.Ichim, Ph.D. – Director

Dr. Ichim was appointed to the Board of Directors on January 22, 2016.  Dr. Ichim is a seasoned biotechnology entrepreneur with a track record of scientific excellence. He has founded/co-founded several companies including Batu Biologics, Inc., Medvax Pharma Corp, ToleroTech Inc, bioRASI, and OncoMune LLC. To date, he has published 99 peer-reviewed articles and is co-editor of the textbooks “RNA Interference: From Bench to Clinical Translation” and “Immuno-Oncology Text Book.”

Dr. Ichim is an ad-hoc editor and sits on several editorial boards. Dr. Ichim is an inventor on over 50 patents and patent applications. Dr. Ichim has extensive experience with stem cell therapy and cellular product development through FDA regulatory pathways. Dr. Ichim spent over 7 years as the President and Chief Scientific Officer of Medistem, developing and commercializing a novel stem cell, the Endometrial Regenerative Cell, through drug discovery, optimization, preclinical testing, IND filing, and up through Phase II clinical trials with the FDA. Dr. Ichim has extensive experience in product development, regulatory filings, and business development.

Dr. Ichim has a BSc in Biology from the University of Waterloo, Waterloo, Ontario, Canada, an MSc in Microbiology and Immunology a University of Western Ontario, London, Ontario, Canada and a Ph.D. in Immunology from the University of Sciences Arts and Technology, Olveston Monserrat.

James Veltmeyer, MD – Chief Medical Officer

Dr. Veltmeyer is a board-certified family physician in La Mesa, California. A graduate of UC San Diego and the Ross University School of Medicine, he completed his residency through the UC San Francisco system where he became Chief of Family Medicine Residency, overseeing 36 doctors.

Dr. Veltmeyer, a member of the San Diego Critical Care Medical Group, has been elected for four years (2012, 2014, 2016, and 2017) by his colleagues in the San Diego County Medical Society as a “Physician of Exceptional Excellence,” the most prestigious honor awarded to a “Top Doctor” in San Diego County. He is among a select group of San Diego physicians who was chosen four of the last fifteen years and he consistently ranks in the top 1% to 2% for patient satisfaction. He is currently the Chief of the Department of Family Medicine at Sharp Grossmont Hospital where he provides senior leadership to over 200 doctors.

Hong Ma, MD, Ph.D., M.B.A. – Chief Scientific Officer

Dr. Ma has an extensive history in academic and translational research. Subsequent to completing her medical degree, she performed basic research in the area of molecular biology of endothelial-associated pathways in her doctorate and postdoctoral studies. She has been critical in establishing numerous ventures and collaborations in the area of biosciences. Dr. Ma has over 20 peer-reviewed publications and has worked with prestigious institutions in the USA, China, and Japan. She received her M.D. from Dalian Medical University, her Ph.D in Cardiovascular Pharmacology at Asahikawa Medical College, and has also earned her MBA at the Rady School of Management at the University of California San Diego.


Share Structure 
https://www.otcmarkets.com/stock/TSOI/security
AS - 1.5 B common , 5 M preferred - https://www.nvsos.gov/SOSEntitySearch/CorpDetails.aspx?lx8nvq=LvtIoYTPV6wB1RIovm008A%253d%253d&nt7=0
IO - 931,175,844
Restricted - 816,540,972
Unrestricted - 114,634,872
Held at DTC - 91,991,872
Float - 70,343,547
SEC Filings  https://www.sec.gov/cgi-bin/browse-edgar?company=therapeutic+solutions+international&match=contains&action=getcompany


Transfer Agent
New Horizon Transfer Inc.
215-515 West Pender Street
Vancouver, BC V6B 6H5
CAN(604) 876-5526
www.newhorizontransfer.com


Contact

Investor Relations
ir@tsoimail.com
Corporate Website
http://therapeuticsolutionsint.com/
Additional info
http://projuvenol.com/
E Commerce Site
http://www.youcanordernow.com/

TSOI on Facebook
https://www.facebook.com/tsoihome/
TSOI on Twitter
https://twitter.com/tsoisupplement


Disclaimer : All of the information presented in the IBOX , Stickies , or posts on this board ,  is based on individual opinions , and is not to be considered as a recommendation to buy , sell , or hold this stock .

Quantum
TSOI
Current Price
Volume:
Bid Ask Day's Range
  • 1D
  • 1M
  • 2M
  • 3M
  • 6M
  • 1Y
  • 2Y
  • 3Y
  • 5Y
TSOI News: Quarterly Report (10-q) 11/14/2018 02:37:32 PM
TSOI News: Therapeutic Solutions International Announces CTE Optimized NeuroStilbene Formulation 10/25/2018 09:00:00 AM
TSOI News: Therapeutic Solutions International Files Patent on Clinical Data Demonstrating Reduction of Inflammatory Cytokines 09/25/2018 09:00:00 AM
TSOI News: Therapeutic Solutions International Collaborates with Internationally Renowned Neurologist and NFL Charger Hall of Famer ... 09/19/2018 09:00:00 AM
TSOI News: Therapeutic Solutions International Completes Phase 1 Clinical Trial in Advanced Cancer Patients for Right to Try Access of... 09/04/2018 09:00:00 AM
PlusOneCoin Top Posts
No plusone'd posts yet. Be the first!
PostSubject
#8730  Sticky Note TSOI DD/NEWS/SS centsability4me 11/05/18 06:39:39 AM
#8750   StemVacs Cancer Vaccine Shows Safety in Phase 1 centsability4me 11/17/18 11:21:54 AM
#8749   New FDA RTT page for patients centsability4me 11/16/18 08:36:25 AM
#8748   FDA commissioner highlights efforts to improve expanded access program centsability4me 11/16/18 07:20:52 AM
#8747   latest 10 Q out centsability4me 11/15/18 06:55:16 PM
#8746   The 4 Stages of CTE centsability4me 11/15/18 05:26:58 PM
#8745   CTE videos centsability4me 11/14/18 12:38:16 PM
#8744   Football Players on NFL's Brain Damage Admission: 'About Time' centsability4me 11/13/18 12:33:41 PM
#8743   this is one of those times , centsability4me 11/13/18 11:27:59 AM
#8742   Nice vol. today , centsability4me 11/12/18 12:48:06 PM
#8741   REPEAT AGAIN !!! corvatsch 11/12/18 12:37:20 PM
#8740   News : 8/22/18 centsability4me 11/12/18 12:17:59 PM
#8739   Repeated Hits to the Head centsability4me 11/12/18 11:03:04 AM
#8738   CTE May occur w/o Concussions centsability4me 11/12/18 06:58:50 AM
#8737   TSOI CTE Patent centsability4me 11/08/18 12:27:06 PM
#8736   You know how much I love the sunshine, Shel_SWFL 11/07/18 04:22:35 PM
#8735   That has gotta be you boxing the stock subslover 11/07/18 04:03:59 PM
#8734   CTE Trail cont. centsability4me 11/07/18 11:52:26 AM
#8733   CTE Trail centsability4me 11/07/18 11:24:55 AM
#8732   agree I do see a lot more research and centsability4me 11/07/18 11:18:58 AM
#8731   What is that phenomenon called, when you purchase Shel_SWFL 11/07/18 07:16:35 AM
#8730   TSOI DD/NEWS/SS centsability4me 11/05/18 06:39:39 AM
#8729   TSOI CTE Formulas centsability4me 11/05/18 06:20:27 AM
#8728   *more stronger MarketStrategy 11/04/18 02:26:22 PM
#8727   Latest PR stated their new formula is 6 MarketStrategy 11/04/18 02:24:38 PM
#8726   TSOI blast from the past . centsability4me 11/04/18 01:26:36 PM
#8725   TSOI and CTE centsability4me 11/04/18 12:08:34 PM
#8724   The latest momo on CTE centsability4me 11/04/18 11:42:37 AM
#8723   for those new here to TSOI centsability4me 11/04/18 02:39:52 AM
#8722   Yeah at least $0.10 a share. The company MarketStrategy 11/03/18 07:00:58 PM
#8721   This will go higher the ten cents in StemCelzRock 11/03/18 05:45:36 PM
#8720   I am not sure what you mean. 10 MEAD II 11/03/18 04:44:48 PM
#8719   This is an easy ten bagger once we MarketStrategy 11/03/18 03:07:06 PM
#8718   I have a very good feeling The few JackAskSlap 11/02/18 07:21:21 PM
#8717   TSOI current patent list centsability4me 11/02/18 03:37:15 PM
#8716   TSOI most recent CTE PR centsability4me 11/02/18 01:25:06 PM
#8715   TSOI CTE centsability4me 11/02/18 12:55:10 PM
#8714   TSOI Team Comments centsability4me 11/02/18 12:18:43 PM
#8713   someone has to centsability4me 11/02/18 12:08:37 PM
#8712   Nice news Cents JackAskSlap 11/01/18 08:33:43 PM
#8711   NEWS 10/25/18 centsability4me 11/01/18 08:27:59 PM
#8710   TSOI DD/NEWS/SS centsability4me 11/01/18 12:31:24 PM
#8709   I DON'T WORRY TOO MUCH HERE IMO. Chaka 11/01/18 04:44:01 AM
#8708   Crazy volume again- just hope we explode north DD_dempsey 11/01/18 02:30:11 AM
#8707   direction first support a 0,004. corvatsch 10/31/18 02:18:56 PM
#8706   it was the quiet centsability4me 10/29/18 12:44:17 PM
#8705   This will move with CELZ shortly here ;) StemCelzRock 10/28/18 02:25:47 PM
#8703   the latest centsability4me 10/28/18 11:53:42 AM
#8702   you are right about centsability4me 10/28/18 11:10:07 AM
#8701   good luck to you also Fred centsability4me 10/27/18 08:33:16 PM
#8700   I understand fred1963 10/27/18 03:00:03 PM
PostSubject